This week, five listed companies including Aisar Bio and Xin Yuan Vision were added for guidance and filing.

Mars Finance News, April 19 — Information disclosed on the website of the China Securities Regulatory Commission shows that this week (April 13 to 19) saw 5 new companies newly filing for listing guidance, namely Shanghai Aisar Biopharmaceutical Co., Ltd., Beijing Core Vision Software Technology Co., Ltd., Raytheon Technologies (Shenzhen) Co., Ltd., Changzhou Mingsai Robotics Technology Co., Ltd., and Beijing Weizhuo Zhiyuan Medical Technology Co., Ltd. Among them, Core Vision and Weizhuo Zhiyuan have already been listed on the National Equities Exchange and Quotations (NEEQ).

Core Vision is an integrated circuit technology services company established in 2002. Relying on its independently developed Electronic Design Automation (EDA) software, the company’s main business covers three major segments: integrated circuit analysis, integrated circuit design, and EDA software licensing.

Weizhuo Zhiyuan was established in 2016 and mainly engages in the R&D and production of smart digital-intelligent surgical equipment and instruments. Financially, as of June 30, 2025, Weizhuo Zhiyuan has not yet turned a profit. In the first half of 2025, revenue was 3.303 million yuan, down 12% year over year; the net loss was 33.6395 million yuan; and its gross margin reached 94%.

In addition, worth noting is that Aisar Biopharmaceutical recently obtained the first national stem cell “Drug Production License” for 2026. Founded in 2013 in Zhangjiang, Shanghai, it is a biopharmaceutical company mainly focused on cell-based drug manufacturing. It is also one of the few domestic enterprises that simultaneously covers two frontier technology fields: mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs). (Ke Gu Bao Broadcast)